文献速递系统性红斑狼疮其他结缔组织病

利妥昔单抗治疗抗磷脂综合征(合并或不合并SLE)的血清学与临床结局

Serological and clinical outcomes of rituximab in antiphospholipid syndrome with or without SLE: a retrospective single-centre cohort.
PubMed 文献 · Rheumatology (Oxford) · 2026-10-29

这项单中心回顾性队列纳入54例接受至少1个疗程利妥昔单抗的抗磷脂综合征患者,其中43例合并SLE。治疗后6-12个月aCL与aβ2GPI的IgG/IgM阳性率显著下降,但定量抑制未长期维持;随访期间5例血栓复发,多数与抗凝不足相关。

要点

  • 利妥昔单抗后6-12个月aPL阳性率显著下降,但长期定量抑制未维持。
  • aCL/aβ2GPI变化未一致反映血栓风险。
  • 血栓复发者多处于未抗凝或INR未达标状态。

核心结论

  • 利妥昔单抗与aPL滴度及阳性率的短期显著下降相关,但定量抑制未能长期维持。
  • aCL/aβ2GPI变化不能一致反映血栓风险,利妥昔单抗或可作为难治性APS的辅助治疗。

研究设计与样本

  • 单中心回顾性队列研究,纳入54例接受至少1个疗程利妥昔单抗的APS患者,其中43例为SLE相关APS。
  • 基线及治疗后6-12个月检测aCL与aβ2GPI的IgG/IgM,中位随访4.7年分析长期血清学、临床与安全性结局。

主要发现

  • 6-12个月时aCL IgG阳性率由59.3%降至24.1%,aCL IgM由24.1%降至5.6%,aβ2GPI IgG由42.6%降至16.7%,aβ2GPI IgM由20.4%降至5.6%(均P<0.05)。
  • 31例有长期血清学数据,末次随访aβ2GPI IgG阳性率仍低于基线(P=0.039),但定量滴度差异不再显著。
  • 长期血清学变化不随利妥昔单抗疗程数不同。
  • 随访期间5例血栓复发,其中4例未抗凝或INR低于治疗范围。

关键数值与推荐

  • aCL IgG阳性率59.3%→24.1%,aCL IgM 24.1%→5.6%,aβ2GPI IgG 42.6%→16.7%,aβ2GPI IgM 20.4%→5.6%(6-12个月,均P<0.05)。
  • 末次随访aβ2GPI IgG阳性率仍低于基线(P=0.039),定量滴度差异无统计学意义。

临床怎么用

  • 利妥昔单抗可考虑用于部分难治性APS患者作为辅助治疗,但需个体化选择。
  • 不应以aCL/aβ2GPI变化作为血栓风险的替代指标,抗凝管理仍是血栓防控关键。

局限性

  • 回顾性单中心设计,样本量小(54例),无法确立因果关系。
  • 长期血清学数据仅31例,可能存在选择偏倚与随访不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the dynamics of aPL titres after rituximab treatment, durability of serological responses, recurrent thrombosis, and safety in patients with APS. METHODS: This retrospective study included 54 patients, predominantly with SLE-associated APS (n = 43), who received at least one course of rituximab. aCL and anti-β2-glycoprotein I (aβ2GPI) IgG/IgM were evaluated at baseline and 6-12 months after treatment. Long-term serological, clinical and safety outcomes were analysed over a median follow-up period of 4.7 years. RESULTS: At 6-12 months, positivity rates decreased significantly for aCL IgG (59.3% to 24.1%), aCL IgM (24.1% to 5.6%), aβ2GPI IgG (42.6% to 16.7%), and aβ2GPI IgM (20.4% to 5.6%) (all P <0.05). Long-term serological data were available for 31 patients. At last follow-up, aβ2GPI IgG positivity remained lower than baseline (P = 0.039), whereas quantitative titres were no longer significantly different. Long-term serological changes did not differ according to rituximab cycle number. Thrombotic recurrence occurred in five patients, four of whom were either off anticoagulation or had subtherapeutic INR values. Fifteen patients developed bacterial infections, seven SARS-CoV-2 infections, and five patients died during follow-up, including one who died from sepsis. CONCLUSION: Rituximab was associated with marked short-term reductions in aPL titres and positivity, although quantitative suppression was not sustained long term. Changes in aCL/aβ2GPI did not consistently reflect thrombotic risk. These findings suggest that rituximab may be a valuable adjunctive therapy in selected patients with difficult-to-treat APS, although causality cannot be established from this retrospective study.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Uludağ, Kemec, Altın, et al. Serological and clinical outcomes of rituximab in antiphospholipid syndrome with or without SLE: a retrospective single-centre cohort. Rheumatology (Oxford). 2026. PMID: 42958956. doi:10.1093/rheumatology/keag609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。